Empagliflozin 10 mg Tablet
Empagliflozin 10mg
Tablet · Prescription medication
KooJoo Pharmaceutical Co., Ltd.
MFDS item code 202102084 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This drug is used in conjunction with dietary and exercise therapy to help control blood sugar in adult patients with type 2 diabetes. It can be administered as monotherapy, and if blood sugar control is difficult, it can be used in combination with other medications such as metformin. In particular, if there is no previous treatment experience or if metformin monotherapy is insufficient, this drug is administered together with metformin. It can also help control blood sugar when used in combination with pioglitazone, sulfonylureas, insulin, and DPP-4 inhibitors. In patients with cardiovascular disease, it should be used cautiously with reference to specialized guidelines. This drug improves blood glucose control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily for monotherapy or as add-on combination therapy with other blood glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. For patients who tolerate this medicine well but have a persistent eGFR of less than 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose of this medicine should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the eGFR decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. This medicine should not be used in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be taken into consideration in patients aged 75 years and older. As clinical experience in older adults aged 85 years and older is limited, initiation of treatment with this medicine is not recommended (see Precautions for Use, section 4. General Precautions).
This drug should not be used in patients with allergy to the active ingredient or components. It should not be administered to patients with type 1 diabetes or severe diabetic ketoacidosis. It is not to be used in patients with severely impaired kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2 or those with end-stage renal disease or on dialysis. This drug contains lactose and should not be administered to patients with genetic metabolic disorders such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. Caution is advised in patients with mildly impaired kidney function, particularly those with a glomerular filtration rate of less than 60 mL/min/1.73m2, where initiation of treatment should be avoided and dose adjustment or discontinuation considered if already under treatment. In patients with heart failure of mild to moderate degree, caution is required; it is not recommended for those with severe heart failure. When used with insulin or sulfonylureas, there is a risk of hypoglycemia, so it may be necessary to adjust the doses of these medications. This drug can induce side effects such as hypoglycemia, genital infections, urinary tract infections, increased urination, and volume depletion, thus patients should seek medical advice immediately if symptoms develop. Particularly, serious metabolic disturbances like ketoacidosis can occur, and if symptoms such as nausea, vomiting, abdominal pain, or difficulty breathing arise, prompt evaluation and treatment is necessary. Elderly patients and those at high risk of volume depletion should be careful of dehydration and hypotension, with regular checks of fluid status recommended. This drug may affect kidney function, so renal function tests should be performed regularly before and during treatment. Women who are pregnant or planning to become pregnant are advised not to use this drug, and breastfeeding mothers should suspend nursing. Safety and efficacy in children under 18 years have not been established, thus use is not recommended. No specific toxic reactions have been reported in the case of overdose, but appropriate care may be needed depending on the clinical situation. This drug may interact with other medications, so it is essential to inform healthcare providers of all other medicines being taken. Caution is advised when driving or operating machinery due to the risk of hypoglycemia. While on this medication, regular consultations with healthcare providers and immediate reporting of any unusual symptoms are necessary.
Not everyone experiences these, and they can vary from person to person.
This drug may be sensitive to air and moisture, so it must be stored in a tightly closed container. It is important to maintain storage temperatures between 1 and 30 degrees Celsius. Doing so will help preserve the drug's efficacy and safety over time.
Light yellow, round, biconvex film-coated tablet
10 tablets/box [10 tablets/PTP X1], 30 tablets/box [10 tablets/PTP X3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
KooJoo Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.